[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338273-105":59,"doc-detail-338273-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","node-sparing-modified-short-course-radiotherapy-capox-and-tislelizumab-for-locally-advanced-mss-or-middle-and-low-rectal-cancer-mrcat-study-protocol","Node-sparing modified short-course Radiotherapy - CAPOX and Tislelizumab - for locally Advanced MSS or Middle and low rectal Cancer (mRCAT) Study Protocol","","Neoadjuvant chemoradiotherapy followed by total mesorectal excision is a standard approach for locally advanced rectal cancer, yet PD-1 blockade is ineffective in most microsatellite stable (MSS) or mismatch repair-proficient (pMMR) tumors. This protocol evaluates whether node-sparing modified short-course radiotherapy combined with chemotherapy and PD-1 blockade can improve responses in MSS/pMMR locally advanced rectal cancer by reducing damage to T lymphocytes and radiation-induced fibrosis. A multicentre, single-arm phase II trial will assess pathological complete response and additional clinical and immunological outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/node-sparing-modified-short-course-radiotherapy-capox-and-tislelizumab-for-locally-advanced-mss-or-middle-and-low-rectal-cancer-mrcat-study-protocol/338273/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/node-sparing-modified-short-course-radiotherapy-capox-and-tislelizumab-for-locally-advanced-mss-or-middle-and-low-rectal-cancer-mrcat-study-protocol/338273.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PD-1 blockade often ineffective in MSS/pMMR locally advanced rectal cancer?","Question",{"text":112,"@type":113},"Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR), for which PD-1 blockade is ineffective. Radiation may help by activating CD8+ T cells and enhancing responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the study design and treatment sequence in this trial?",{"text":117,"@type":113},"This is an open-label, single-arm, multicentre, prospective phase II trial. Patients receive node-sparing modified short-course radiotherapy followed by CAPOX and tislelizumab starting two days after radiotherapy completion.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the primary endpoint of the trial?",{"text":121,"@type":113},"The primary endpoint is the rate of pathological complete response. Secondary outcomes include organ preservation rate, tumor regression grade, local recurrence, survival, adverse effects, and quality of life.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338273,1790154893,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Cai etal. BMC Cancer (2024) 24:1247 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12994-0](https://doi.org/10.1186/s12885-024-12994-0)  \nSTUDY PROTOCOL Open Access  \nNode-sparing modified short-course Radiotherapy Combined with CAPOX and Tislelizumab for locally Advanced MSSof Middle and low rectal Cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial  \nCheng Cai 1,2†, Xia Zhang3†, Xiaonan Sun4, Huogang Wang2,5,6, Engeng Chen2, Li Chen2, Benxing Gu4, Jianping Wang 1, Xuefeng Huang2, Weifeng Lao2, Xiaowei Wang2, Min Chen2, Shubo Ding7, Jinlin Du 1* and Zhangfa Song2,5,6*  \nAbstract  \nBackground Neoadjuvant chemoradiotherapy followed by total mesorectal excision is a standard treatment for locally advanced rectal cancer. Mismatch repair-deficient locally advanced rectal cancer (LARC) was highly sensitive to PD-1 blockade. However, most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) subtypes for which PD-1 blockade is ineffective. Radiation can trigger the activation of CD8 + T cells, further enhancing the responses of MSS/pMMR rectal cancer to PD-1 blockade. Radioimmunotherapy offers a promising therapeutic modality for rectal cancer. Progenitor T exhausted cells are abundant in tumour-draining lymph nodes and play an important role in immunotherapy. Conventional irradiation fields include the mesorectum and regional lymph nodes, which might cause considerable damage toT lymphocytes and radiation-induced fibrosis, ultimately leading to a poor response to immunotherapy and rectal fibrosis. This study investigated whether node-sparing modified short-course irradiation combined with chemotherapy and PD-1 blockade could be effective in patients with MSS/ pMMR LARC.  \nMethods This was a open-label, single-arm, multicentre, prospective phase II trial. 32 LARC patients with MSS/pMMR will receive node-sparing modified short-course radiotherapy (the irradiated planned target volume only included the primary tumour bed but not the tumour-draining lymph nodes, 25 Gy/5f, 5 Gy/f ) followed by CAPOX and  \n†Cheng Cai and Xia Zhang contributed equally to this work.  \n*Correspondence:  \nJinlin Du [djl9090@163.com](djl9090@163.com)[ ](djl9090@163.com)Zhangfa Song [songzhangfa@zju.edu.cn](songzhangfa@zju.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nCai et al. BMC Cancer (2024) 24:1247 Page 2 of 7  \ntislelizumab. CAPOX and tislelizumab will be started two days after the completion of radiotherapy: oxal iplatin 130 mg/m2 intravenous infusion, day 1; capecitabine 1000 mg/m2 oral administration, days 1–14; and tislelizumab 200 mg, intravenous infusion, day 1. There will be four 21-day cycles. TME will be performed at weeks 14–15. We will collect blood, tumour, and lymphoid specimens; perform flow cytometry and in situ multiplexed immunofluorescence detection; and analyse t","cbCaimFrUwA9GJ7e","https://ap.wps.com/l/cbCaimFrUwA9GJ7e","pdf",1129858,"English","# Abstract\n## Background\n## Methods\n## Discussion\n## Trial registration\n## Keywords","[{\"question\":\"Why is PD-1 blockade often ineffective in MSS/pMMR locally advanced rectal cancer?\",\"answer\":\"Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR), for which PD-1 blockade is ineffective. Radiation may help by activating CD8+ T cells and enhancing responses.\"},{\"question\":\"What is the study design and treatment sequence in this trial?\",\"answer\":\"This is an open-label, single-arm, multicentre, prospective phase II trial. Patients receive node-sparing modified short-course radiotherapy followed by CAPOX and tislelizumab starting two days after radiotherapy completion.\"},{\"question\":\"What is the primary endpoint of the trial?\",\"answer\":\"The primary endpoint is the rate of pathological complete response. Secondary outcomes include organ preservation rate, tumor regression grade, local recurrence, survival, adverse effects, and quality of life.\"}]","Node-sparing modified short-course Radiotherapy - CAPOX and Tislelizumab - for locally Advanced MSS or Middle and low rectal Cancer (mRCAT) Study Protocol | PDF",1790022865,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b13bca669e6c6cf62136a96714104312.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb99e7114fc83ff87a07687a1635552c.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90e89fb7f87699062115740d5f23b39a.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2969526abc3d496fa85678b58a9e3b6b.webp",980,1306]